Immunotherapy and stereotactic ablative radiotherapy (ISABR): A curative approach?

Nature Reviews Clinical Oncology

Volumn 13, Issue 8, 2016, Pages 516-524

  Bernstein, Michael B ^a   Krishnan, Sunil ^a   Hodge, James W ^a   Chang, Joe Y ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; FRESOLIMUMAB; INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; TUMOR ANTIGEN; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; BRAIN CANCER; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CLINICAL EFFECTIVENESS; DENDRITIC CELL; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOSTIMULATION; LIVER CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTATIC MELANOMA; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; STEREOTACTIC RADIOSURGERY; T LYMPHOCYTE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); FORECASTING; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PROCEDURES; RADIOSURGERY;

ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; FORECASTING; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; RADIOSURGERY;

EID: 84960158712     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2016.30     Document Type: Review

References (75)

1. Imaizumi, N., Monnier, Y., Hegi, M., Mirimanoff, R. O., & Ruegg, C. Radiotherapy suppresses angiogenesis in mice through TGF-βRI/ALK5 dependent inhibition of endothelial cell sprouting. PLoS ONE 5, e11084 (2010)
2. Kamrava, M., Bernstein, M. B., Camphausen, K., & Hodge, J. W. Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination?. Mol. Biosyst. 5, 1262-1270 (2009).
3. Chen, Z. et al. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int. J. Cancer 93, 539-548 (2001)
4. Kotera, Y., Shimizu, K., & Mule, J. J. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res. 61, 8105-8109 (2001)
5. Melcher, A., Gough, M., Todryk, S., & Vile, R. Apoptosis or necrosis for tumor immunotherapy: whats in a name?. J. Mol. Med. (Berl.) 77, 824-833 (1999)
6. Yu, P., Rowley, D. A., Fu, Y. X., & Schreiber, H. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr. Opin. Immunol. 18, 226-231 (2006)
7. Ma, Y., Aymeric, L., Locher, C., Kroemer, G., & Zitvogel, L. The dendritic cell-tumor cross-talk in cancer. Curr. Opin. Immunol. 23, 146-152 (2011)
8. McBride, W. H. et al. A sense of danger from radiation. Radiat. Res. 162, 1-19 (2004)
9. Demaria, S., Bhardwaj, N., McBride, W. H., & Formenti, S. C. Combining radiotherapy and immunotherapy: a revived partnership. Int. J. Radiat. Oncol. Biol. Phys. 63, 655-666 (2005)
10. Friedman, E. J. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr. Pharm. Des. 8, 1765-1780 (2002)
11. Kwilas, A. R., Donahue, R. N., Bernstein, M. B., & Hodge, J. W. In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front. Oncol. 2, 104 (2012)
12. Gameiro, S. R. et al. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T cell killing. Oncotarget 5, 403-416 (2014)
13. Hodge, J. W., Ardiani, A., Farsaci, B., Kwilas, A. R., & Gameiro, S. R. The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin. Oncol. 39, 323-339 (2012)
14. Gameiro, S. R., Caballero, J. A., Higgins, J. P., Apelian, D., & Hodge, J. W. Exploitation of differential homeostatic proliferation of T cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunol. Immunother. 60, 1227-1242 (2011)
15. Hodge, J. W. et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int. J. Cancer 133, 624-636 (2013)
16. Reits, E. A. et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203, 1259-1271 (2006)
17. Chang, J. Y. et al. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer. Cancer 119, 3402-3410 (2013)
18. Palma, D. A. et al. The oligometastatic state - separating truth from wishful thinking. Nat. Rev. Clin. Oncol. 11, 549-557 (2014)
19. Timmerman, R. D., Herman, J., & Cho, L. C. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J. Clin. Oncol. 32, 2847-2854 (2014)
20. Bernstein, M. B. et al. Radiation-induced modulation of costimulatory and coinhibitory T cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer Biother. Radiopharm. 29, 153-161 (2014)
21. Schaue, D., Ratikan, J. A., Iwamoto, K. S., & McBride, W. H. Maximizing tumor immunity with fractionated radiation. Int. J. Radi. Oncol. Biol. Phys. 83, 1306-1310 (2012)
22. Formenti, S. C., & Demaria, S. Radiation therapy to convert the tumor into an in situ vaccine. Int. J. Radi. Oncol. Biol. Phys. 84, 879-880 (2012)
23. Zhang, H. et al. An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy. PLoS ONE 7 38111 (2012)
24. Lee, Y. et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114, 589-595 (2009)
25. Lugade, A. A. et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174, 7516-7523 (2005)
26. Nishikawa, H., & Sakaguchi, S. Regulatory T cells in tumor immunity. Int. J. Cancer 127, 759-767 (2010)
27. Aryankalayil, M. J. et al. Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells. Radiat. Res. 182, 139-148 (2014)
28. Said, E. A. et al. Programmed death 1 induced interleukin 10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat. Med. 16, 452-459 (2010)
29. Egen, J. G., Kuhns, M. S., & Allison, J. P. CTLA 4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3, 611-618 (2002)
30. Demaria, S. et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA 4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11, 728-734 (2005)
31. Dewan, M. Z. et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA 4 antibody. Clin. Cancer Res. 15, 5379-5388 (2009)
32. Verbrugge, I. et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 72, 3163-3174 (2012)
33. Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373-377 (2015)
34. Zegers, C. M. et al. Radiotherapy combined with the immunocytokine L19 IL2 provides long-lasting antitumor effects. Clin. Cancer Res. 21, 1151-1160 (2015)
35. Postow, M. A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925-931 (2012)
36. Hodge, J. W., Sharp, H. J., & Gameiro, S. R. Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. Cancer Biother. Radiopharm. 27, 12-22 (2012)
37. Hiniker, S. M. et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl. Oncol. 5, 404-407 (2012)
38. Golden, E. B., Demaria, S., Schiff, P. B., Chachoua, A., & Formenti, S. C. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol. Res. 1, 365-372 (2013)
39. Silk, A. W., Bassetti, M. F., West, B. T., Tsien, C. I., & Lao, C. D. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med. 2, 899-906 (2013)
40. Stamell, E. F., Wolchok, J. D., Gnjatic, S., Lee, N. Y., & Brownell, I. The abscopal effect associated with a systemic anti-melanoma immune response. Int. J. Radiat. Oncol. Biol. Phys. 85, 293-295 (2013)
41. Karbach, J. et al. Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates. Cancer Immunol. Res. 2, 404-409 (2014)
42. Kiess, A. P. et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int. J. Radiat. Oncol. Biol. Phys. 92, 368-375 (2015)
43. Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184 043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 700-712 (2014)
44. Seung, S. K. et al. Phase 1 study of stereotactic body radiotherapy and interleukin 2 - Tumor and immunological responses. Sci. Transl. Med. 4, 137ra174 (2012)
45. US National Library of Science. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01950195?term=NCT01950195&rank=1 (2014)
46. US National Library of Science. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/results?term=NCT01497808&Search=Search (2014)
47. US National Library of Science. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02239900?term=NCT02239900&rank=1 (2014)
48. Crittenden, M. et al. Current clinical trials testing combinations of immunotherapy and radiation. Semin. Radiat. Oncol. 25, 54-64 (2015)
49. Chang, J. Y. et al. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat. Oncol. 7, 152 (2012)
50. Timmerman, R. et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303, 1070-1076 (2010)
51. Senthi, S., Lagerwaard, F. J., Haasbeek, C. J., Slotman, B. J., & Senan, S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol. 13, 802-809 (2012).
52. Timmerman, R. et al. RTOG 0618: tereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients. J. Clin. Oncol. 31, S7523 (2013)
53. Chang, J. Y. et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 16, 630-637 (2015)
54. Shirvani, S. M. et al. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg. 149, 1244-1253 (2014)
55. Vansteenkiste, J. F. et al. MAGRIT, a double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of the recMAGE A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE A3 positive non-small cell lung cancer (NSCLC). Presented at the European Society for Medical Oncology, Madrid Spain (2014)
56. US National Library of Science. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02086721?term=NCT02086721&rank=1 (2015)
57. Kalbasi, A., June, C. H., Haas, N., & Vapiwala, N. Radiation and immunotherapy: a synergistic combination. J. Clin. Invest. 123, 2756-2763 (2013).
58. Young, K., Cottam, B., Baird, J. R., Gough, M. J., & Crittenden, M. Ideal timing of immunotherapy with radiation in murine tumor models. Int. J. Radiat. Oncol. 90 58 (2014)
59. Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48-61 (2015)
60. Henn, B. M., Botigue, L. R., Bustamante, C. D., Clark, A. G., & Gravel, S. Estimating the mutation load in human genomes. Nat. Rev. Genet. 16, 333-343 (2015)
61. Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD 1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015)
62. Cha, E. et al. Improved survival with T cell clonotype stability after anti-CTLA 4 treatment in cancer patients. Science Transl. Med. 6, 238ra270 (2014)
63. Kwek, S. S. et al. Diversity of antigen-specific responses induced in vivo with CTLA 4 blockade in prostate cancer patients. J. Immunol. 189, 3759-3766 (2012)
64. Disis, M. L. et al. HER 2/neu vaccine-primed autologous T cell infusions for the treatment of advanced stage HER 2/neu expressing cancers. Cancer Immunol. Immunother. 63, 101-109 (2014)
65. Gulley, J. L. et al. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol. Res. 2, 133-141 (2014)
66. Rosenberg, S. A. et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol. 175, 6169-6176 (2005)
67. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012)
68. US National Library of Science. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01862900?term=NCT01862900&rank=1 (2015)
69. US National Library of Science. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01769222?term=NCT01769222&rank=1 (2013)
70. US National Library of Science. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01401062?term=NCT01401062&rank=1 (2015)
71. US National Library of Science. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02298946?term=NCT02298946&rank=1 (2015)
72. US National Library of Science. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01703507?term=NCT01703507&rank=1 (2015)
73. US National Library of Science. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02444741?term=NCT02444741&rank=1 (2015)
74. Bolli, M. et al. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-Associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann. Surg. 236, 785-793; discussion 793 (2002)
75. Jungbluth, A. A. et al. Expression of MAGE-Antigens in normal tissues and cancer. Int. J. Cancer 85, 460-465 (2000)